⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL772328 | 0.79 | — | — | |
| SCHEMBL20678849 | 0.72 | — | — | |
| SCHEMBL20678847 | 0.72 | — | — | |
| SCHEMBL680631 | 0.72 | — | — | |
| SCHEMBL24679 | 0.71 | — | — | |
| SCHEMBL20678991 | 0.67 | — | — | |
| SCHEMBL1806138 | 0.67 | — | — | |
| SCHEMBL1259601 | 0.67 | — | — | |
| SCHEMBL3530229 | 0.65 | — | — | |
| SCHEMBL2109467 | 0.65 | ALDH1A1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040099-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2021-02-11 | — | — | US | claimed |
| CN-112312909-A | Compounds for the treatment of kinase-dependent disorders | 埃克塞里艾克西斯公司 | 2021-02-02 | — | — | CN | claimed |
| EP-3743068-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2020-12-02 | — | — | EP | claimed |
| WO-2019148036-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS, INC. (US) | 2019-08-01 | — | — | WO | claimed |
| WO-2011073273-A1 | BENZOXAZINE ARYL SULFONAMIDE DERIVATIVES AS KV1.3 MODULATORS | EVOTEC AG (DE) | 2011-06-23 | — | — | WO | claimed |
| CN-112312909-B | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-07-02 | — | — | CN | disclosed |
| EP-3694846-B1 | 1-BENZYL-2-IMINO-4-PHENYL-5-OXOIMIDAZOLIDINE DERIVATIVES AS HIV PROTEASE INHIBITORS | GILEAD SCIENCES INC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20230374024-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11708367-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11352329-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210078959-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2021-03-18 | — | — | US | disclosed |
| US-20210040099-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2021-02-11 | — | — | US | disclosed |
| US-10774053-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| EP-3694846-A1 | 1-BENZYL-2-IMINO-4-PHENYL-5-OXOIMIDAZOLIDINE DERIVATIVES AS HIV PROTEASE INHIBITORS | Gilead Sciences, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| CN-111212832-A | 1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as HIV protease inhibitors | 吉利德科学公司 | 2020-05-29 | — | — | CN | disclosed |
| WO-2019148036-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-07-11 | — | — | US | disclosed |
| WO-2019075291-A1 | 1-BENZYL-2-IMINO-4-PHENYL-5-OXOIMIDAZOLIDINE DERIVATIVES AS HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-04-18 | — | — | WO | disclosed |
| WO-2011073273-A1 | BENZOXAZINE ARYL SULFONAMIDE DERIVATIVES AS KV1.3 MODULATORS | EVOTEC AG (DE) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011073277-A1 | PIPERIDINE ARYL SULFONAMIDE DERIVATIVES AS Kv1.3 MODULATORS | EVOTEC AG (DE) | 2011-06-23 | — | — | WO | disclosed |